+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
All Ages
All Genders
ID06480383

Evaluating ITI-1284 as an Additional Treatment for Adults with Generalized Anxiety Disorder Not Responding Adequately to Current Therapy

Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03

705

Participants Needed

59

Research Sites

31 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness, safety, and tolerability of ITI-1284 as an additional treatment for adults with Generalized Anxiety Disorder GAD who have not had sufficient improvement from their current GAD medication. This study is a multicenter, randomized, double-blind, placebo-controlled trial focusing on patients diagnosed with moderate to severe GAD according to the DSM-5-TR criteria. Participants are randomly assigned to one of three groups to receive either ITI-1284 10 mg, ITI-1284 20 mg, or a matching placebo. All treatments are administered as once-daily sublingual tablets alongside their ongoing GAD therapy. The study treatment period lasts for six weeks, during which participants continue their existing GAD medication at stable doses. Throughout the study, participants will undergo assessments including the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S to measure anxiety symptoms and overall severity. The primary outcome is measured at week 6. Safety and tolerability are monitored closely during visits. The total duration of participation aligns with the six-week treatment period.

CONDITIONS

Brief Title

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here